#Incretin mimetics
GLP-1, GIP, glucagon receptor agonists.
US employers pulling GLP-1 coverage in 2027
About 14% of large US employers have dropped or plan to drop GLP-1 obesity drug coverage in 2027, as pharmacy costs hit 25% of total healthcare spend.
GLP-1 Drugs and Kidney Fibrosis in Mice
A new mouse study compared semaglutide, tirzepatide and retatrutide on kidney fibrosis. Here is what the animal data does and does not show.
Switching to Tirzepatide: Liver Fibrosis
A Japanese study found switching from other GLP-1 drugs to tirzepatide reduced FIB-4 liver fibrosis scores in high-risk patients.
Can incretins ease psoriasis inflammation?
A 2026 editorial asks whether tirzepatide-class incretin therapy quiets inflammation biologics leave behind in psoriasis. A hypothesis, not a trial result.
What is GEP44? A GLP-1/PYY explainer
GEP44 is an investigational peptide that pairs GLP-1 with peptide YY signalling to test whether weight loss can come with fewer GI side effects.
COMBINE 4: IcoSema vs insulin glargine
COMBINE 4 put once-weekly IcoSema against daily insulin glargine U100 in type 2 diabetes. HbA1c fell further, and bodyweight moved the other way.
Do GLP-1 drugs cause throat symptoms?
A 2026 Laryngoscope cohort ties GLP-1 drugs to cough, globus and voice change. Here is what an association study can and cannot show.
Stapled semaglutide variants, explained
A new chemistry paper built stapled variants of a semaglutide fragment that last longer in serum; here is what that does and does not show.
Tirzepatide: 10-year CVD risk in SURMOUNT-1
Post-hoc SURMOUNT-1 analysis: tirzepatide 15 mg cut predicted 10-year CVD risk by 1.92 pp at 72 weeks, widening to a 5.15 pp gap over placebo at three years.
Oral GLP-1 drugs for obesity, no diabetes
A 2026 network meta-analysis of nine trials ranks oral semaglutide and orforglipron as top performers for weight loss in adults with obesity without diabetes.
Zepbound versus obesity pills
Zepbound still has strong direct trial evidence as oral obesity medicines add useful, but not automatically superior, options.
Tirzepatide and heart events: BMJ study
A 2026 BMJ cohort linked tirzepatide to fewer cardiovascular events than sitagliptin, but the result remains observational.